SoftBank-backed Noah Medical plans $100m Hong Kong IPO. SoftBank-backed Noah Medical, a US-headquartered medical robotics company, is preparing for a Hong Kong initial public offering that could raise more than US$100 million, founder Zhang Jian said. The company could file for the listing as early as next year, Zhang said the company chose Hong Kong to support its expansion in mainland China after winning approval from China's drug regulator in November last year. Noah plans to sell more surgical robots in top-tier and emerging mainland cities, including Hangzhou. It is targeting Sir Run Run Shaw Hospital there. Zhang added that Hong Kong's Prince of Wales Hospital bought Noah's equipment. Noah's flagship Galaxy System, used for robotic navigated bronchoscopy, received US Food and Drug Administration clearance in 2023. About 90% of Noah's revenue comes from the US, where its surgical robots have been used to treat about 15,000 patients, according to Zhang. Before the planned initial public offering, Noah raised US$150 million in a 2023 series B round. Stay updated on the go with our mobile app. Get latest insights with smoother, more personalized experience through TIA mobile app. How would you feel if you could no longer use Tech in Asia? Share, tag us, and land on our Wall of!

Noah Medical announces galaxy(tm) II. 11th, August 2026 2 mins read Noah Medical has announced the commercial launch of the Galaxy II software, the next evolution of the company's robotic-assisted bronchoscopy (RAB) platform. The Galaxy II software gives physicians imaging flexibility and procedural control to take on their most complex cases with confidence, advancing what bronchoscopy can deliver across every dimension of the procedure. Lung cancer remains the leading cause of cancer death worldwide, and survival depends heavily on early diagnosis, making the ability to accurately biopsy small, hard-to-reach lung lesions one of the most consequential steps in a patient's path to treatment. At the center of the system is Dual-Mode Imaging, which lets physicians move seamlessly between Galaxy's High- Definition Digital Tomosynthesis (HD-DT) and Cone-Beam CT (CBCT) at any point in a procedure. HD-DT delivers efficiently and effectively across the vast majority of cases at a fraction of the radiation dose, while CBCT is available at the moment a case calls for more. The result puts the imaging decision where it belongs, in the physician's hands. "Galaxy II software puts physicians in control of their imaging strategy for every procedure," said Jian Zhang, founder and CEO of Noah Medical. "By bringing HD-DT, CBCT, and advanced robotic control together in one platform using the Galaxy II software, we let physicians choose what each case requires, enabling them to adapt to each patient's anatomy and reduce radiation exposure while maximizing procedural efficiency." Accurately reaching and sampling small pulmonary lesions remains difficult due to two persistent challenges: CT-to-Body Divergence, where the preoperative CT no longer matches the patient's anatomy during the procedure, and Tool-Tissue Divergence, where a biopsy tool drifts from its intended path even when the catheter is well positioned. Galaxy II software addresses both by uniting navigation, imaging, and real-time confirmation of the lesion and tool in a single platform. "The Galaxy System's unique ability to correct for tool-tissue divergence in real time drives its high diagnostic yield, giving physicians confidence that their biopsy tool is exactly where they intend it," said Dr. Francisco Almeida, Interventional Pulmonologist at City of Hope(R) Cancer Center Atlanta. "Galaxy II software builds on that foundation, enhancing navigation, imaging, and confirmation in a single platform. It puts the choice of imaging modality in the physician's hands, so procedures run more efficiently while also cutting the radiation burden on patients and clinicians."